Emergent BioSolutions Inc.

NYSE:EBS

8.1 (USD) • At close December 20, 2024
Overview | Financials

Numbers are in millions (except for per share data and ratios) USD.

20232022202120202019201820172016201520142013201220112010200920082007200620052004200320022001
Revenue 1,049.31,120.91,792.71,555.41,106782.4560.873488.782522.789450.138312.745281.888273.384286.171234.786178.554182.915152.732130.68883.49455.76978.54145.309
Cost of Revenue 705.4693.7757.5524433.5322.3195.707131.284124.295118.41262.12746.07742.17147.11446.26234.08140.30924.12531.60330.102024.569424.1
Gross Profit 343.9427.21,035.21,031.4672.5460.1365.166357.498398.494331.726250.618235.811231.213239.057188.524144.473142.606128.60799.08553.39255.76953.972-378.791
Gross Profit Ratio 0.3280.3810.5770.6630.6080.5880.6510.7310.7620.7370.8010.8370.8460.8350.8030.8090.780.8420.7580.63910.687-8.36
Reseach & Development Expenses 111.4193234234.5226.2142.897.384108.29153.997150.829119.933120.226124.83289.29574.58859.4753.95845.50118.38110.11702.808193
General & Administrative Expenses 00000202.5143.497143.686148.458122.84187.88376.018076.20573.78655.07655.555000000
Selling & Marketing Expenses 00000000000000000000000
SG&A 368.4340.3348.4303.3273.5202.5143.497143.686148.458122.84187.88376.01874.28276.20573.78655.07655.55544.60142.79330.323013.397340.3
Other Expenses 564.259.958.559.858.71.6-0.8150.263-0.3192.9260.4261.970000016.575-10000336.2
Operating Expenses 1,044593.2640.9597.6558.4370.3240.881251.976302.455273.67207.816196.244199.114165.5148.374114.546109.51390.10251.17440.44016.205869.5
Operating Income -726.4-166352.6433.8114.189.8124.285105.52296.03958.05642.80229.96732.09973.55740.1529.92733.09338.02821.33616.77155.76937.767-0.364
Operating Income Ratio -0.692-0.1480.1970.2790.1030.1150.2220.2160.1840.1290.1370.1060.1170.2570.1710.1680.1810.2490.1630.20110.481-0.008
Total Other Income Expenses Net -4.8-53-38.2-26.6-36.7-8.3-5.7-6.301-5.798-4.9940.5652.098-0.156-0.1911.3612.0862.894-0.49-16.802-0.17-55.769-0.642-0.19
Income Before Tax -731.2-221.7314.4407.277.481.5118.63399.22189.76953.06243.36732.06531.94373.36641.51132.73735.98738.01521.10916.601037.125-0.554
Income Before Tax Ratio -0.697-0.1980.1750.2620.070.1040.2120.2030.1720.1180.1390.1140.1170.2560.1770.1830.1970.2490.1620.19900.473-0.012
Income Tax Expense 29.32.183.5102.122.918.836.03936.69726.89916.32113.10813.92215.8326.18214.96612.05513.05115.2225.3255.129-4.4540.7332.1
Net Income -760.5-223.8219.5305.854.562.782.59451.77662.8736.74131.13523.52423.01951.69831.14420.68222.93622.79315.78411.4724.45436.392-0.554
Net Income Ratio -0.725-0.20.1220.1970.0490.080.1470.1060.120.0820.10.0830.0840.1810.1330.1160.1250.1490.1210.1370.080.463-0.012
EPS -14.85-4.474.15.791.061.251.981.291.630.980.860.650.651.631.020.690.790.990.770.610.241.97-0.03
EPS Diluted -14.85-4.474.065.671.041.221.711.131.410.880.850.650.641.590.990.680.770.930.690.560.221.75-0.03
EBITDA -505.3-32.9458.2549227.3152.7158.13145.067177.57493.75562.32543.26841.29879.35646.51737.02437.9143.88225.42518.70955.76937.76745.309
EBITDA Ratio -0.482-0.0310.2870.3560.2050.1490.2230.2190.2520.2080.1990.1880.1520.2810.1980.1950.2060.2840.520.13210.4841.003